[A18-74] Alirocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Last updated 01.02.2019
Project no.:
A18-74
Commission:
Commission awarded on 31.10.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Primary hypercholesterolaemia or mixed dyslipidaemia
Added benefit neither proven for patients for whom statin therapy is an option nor for patients with intolerance or contraindication to statin therapy
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A15-47 | Alirocumab - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-136 | Alirocumab (hypercholesterolaemia) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-05-02 A G-BA decision was published.